Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Reaffirmed by Robert W. Baird

Robert W. Baird restated their sell rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note published on Friday morning. The firm currently has a $408.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the company. Canaccord Genuity set a $484.00 price objective on Regeneron Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, June 20th. Credit Suisse Group reissued a buy rating and set a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, May 15th. BTIG Research reissued a buy rating and set a $540.00 price objective (up from $480.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, June 30th. BidaskClub cut Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, July 6th. Finally, Bank of America Corporation reissued a buy rating and set a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $496.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 445.11 on Friday. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The stock has a 50 day moving average price of $482.49 and a 200-day moving average price of $444.41. The stock has a market capitalization of $47.20 billion, a PE ratio of 44.65 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The business’s revenue was up 21.2% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/09/12/regeneron-pharmaceuticals-inc-regn-stock-rating-reaffirmed-by-robert-w-baird.html.

In related news, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares of the company’s stock, valued at $23,405,572.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 129,257 shares of company stock valued at $61,745,394 in the last three months. 10.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares in the last quarter. Concert Wealth Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.4% during the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 3 shares in the last quarter. Cleararc Capital Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.3% during the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after purchasing an additional 5 shares in the last quarter. Regentatlantic Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 5 shares in the last quarter. Finally, Capital Planning Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 12 shares in the last quarter. 67.96% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply